TrialBlood cancer journal2015

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.

A Pardanani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.